Main Product Candidates

Fully Owned Product	Candidate / Target	Indication	Study	Preclinical	Phase 1 Dose Escalation	Phase 1 Dose Expansion	Pivotal Phase (2)
	UCART22	Acute Lymphoblastic Leukemia	BALLI-01	UCART22 What is UCART22?  UCART22 is an allogeneic CAR T-cell product candidate targeting CD22. UCART22 is being evaluated in patients with relapsed or refractory B- cell acute lymphoblastic leukemia (r/r B-ALL). BALLI-01 clinical study (evaluating UCART22)  BALLI-01, is a Phase 1/2a open-label dose-escalation and dose-expansion study, designed to evaluate the safety, expansion, persistence and clinical activity of UCART22 in patients with relapsed or refractory B- cell acute lymphoblastic leukemia.
	UCART123	Acute Myeloid Leukemia	AMELI-01	UCART123 What is UCART123?  UCART123 is an allogeneic CAR T-cell product candidate targeting CD123. UCART123 is being evaluated in patients with relapsed or refractory acute myeloid leukemia (r/r AML). AMELI-01 clinical study (evaluating UCART123)  AMELI-01, is a Phase 1, open-label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 in patients with relapsed or refractory acute myeloid leukemia.
	UCART20x22	Non Hodgkin Lymphoma	NatHaLi-01	UCART20x22 What is UCART20X22?  UCART20x22 is Cellectis’ first allogeneic dual CAR T-cell product candidate, targeting CD20 and CD22, being developed for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL). Dual targeting is designed to enhanced tumor cell killing and to prevent immune escape due to single antigen targeting UCART20x22 is Cellectis’ first product candidate fully developed and manufactured internally. NatHaLi-01 study (evaluating UCART20x22) NatHaLi-01, is a Phase 1/2a open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART20x22 in patients with relapsed and refractory B-Cell Non-Hodgkin Lymphoma.
Licensed to:
	ALLO-501A ¹	Large B-cell Lymphoma	ALPHA2	ALLO501 and ALLO-501A The following information are based on information provided or otherwise publicly reported by our licensed partners: ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier (the “Servier Agreement”). Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. In September 2022, Servier communicated that it was discontinuing its involvement in the development of in-licensed CD19 products and is providing Allogene with the ability to elect to obtain a license to the CD19 Products outside of the United States. What are ALLO-501 and 501A? ALLO-501 and ALLO-501A are anti-CD19 allogeneic CAR T (AlloCAR T™) products in development for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). ALLO-501A, a next-generation anti-CD19 AlloCAR T™ being studied in a potentially Pivotal Phase 2 trial, eliminates the rituximab recognition domains in ALLO-501, which could allow for use in a broader patient population, including LBCL patients with recent rituximab exposure. ALPHA Study (evaluating ALLO-501) Enrollment in the Phase 1 ALLO-501 ALPHA trial in r/r LBCL has completed accrual. ALPHA2 Study (evaluating ALLO-501A) Primary Endpoints: Safety and tolerability Overall response rate Key Secondary Endpoints: ALLO-501A cell kinetics Allogene’s AlloCAR T™ programs utilize Cellectis technologies. AlloCAR T™ is a trademarks of Allogene Therapeutics, Inc.
	ALLO-715 ³	Multiple Myeloma	UNIVERSAL	ALLO-715 The following information are based on information provided or otherwise publicly reported by our licensed partners: Allogene’s anti-BCMA programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these programs. What is ALLO-715? ALLO-715 is an allogeneic CAR T AlloCAR T™ cell therapy that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma. UNIVERSAL Study (evaluating ALLO-715): Primary Objective: Safety and tolerability Key Secondary Objectives: Recommended ALLO-715 Phase 2 dose and lymphodepletion regimen Anti-tumor activity (ORR, duration of response, PFS, and MRD) ALLO-715 cellular kinetics (blood levels of anti-BCMA CAR T cells) Allogene’s AlloCAR T™ programs utilize Cellectis technologies. AlloCAR T™ is a trademarks of Allogene Therapeutics, Inc.
	ALLO-605 ³	Multiple Myeloma	IGNITE	ALLO-605 The following information are based on information provided or otherwise publicly reported by our licensed partners: Allogene’s anti-BCMA programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these programs. What is ALLO-605? ALLO-605 is a next-generation AlloCAR T™ investigational therapy that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma. ALLO-605 incorporates Allogene’s proprietary TurboCAR™ technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. IGNITE Study (evaluating ALLO-605) Primary Endpoints: Safety and tolerability Secondary Endpoints: Anti-tumor activity and cellular kinetics of ALLO-605 Evaluate immunogenicity against ALLO-605 Evaluate responses in subjects with previous treatment with an anti-BCMA targeted therapy Allogene’s AlloCAR T™ programs utilize Cellectis technologies. AlloCAR T™ and TurboCAR™ are trademarks of Allogene Therapeutics, Inc.
	ALLO-316 ⁴	Renal Cell Carcinoma	TRAVERSE	ALLO-316 The following information are based on information provided or otherwise publicly reported by our licensed partners: Allogene’s anti-CD70 programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these programs. What is ALLO-316? ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, and Allogene’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). TRAVERSE Study (evaluating ALLO-316) Primary endpoints: Safety and tolerability Secondary endpoints: Anti-tumor efficacy Allogene’s AlloCAR T™ programs utilize Cellectis technologies. AlloCAR T™ is a trademarks of Allogene Therapeutics, Inc.

1 ALLO-501A is exclusively licensed to Servier and under a joint clinical development program between Servier and Allogene. The ALPHA2 study targets Large B-Cell Lymphoma (LBCL)
2 Phase 3 may not be required if Phase 2 is registrational.
3 ALLO-715 and ALLO-605 utilize TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the BCMA target. Allogene holds global development and commercial rights for this investigational candidate
4 CD70 is a licensed target from Cellectis. ALLo-316 utilize TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the CD70 target. Allogene holds global development and commercial rights for this investigational candidate.

Development of a product candidate takes place in several stages

Discovery: Identification of a new potential target that could lead to a future product candidate.
Product development: Engineering of “Chimeric Antigen Receptor” (CAR) T-cells is one of the technologies developed by Cellectis to construct new product candidates. This approach allows us to design allogeneic product candidates through a gene editing mechanism of T-cells derived from healthy donors. Gene editing is performed using TALEN®, which allow very precise and targeted gene modification and provide new attributes to the product such as additional levels of safety or compatibility with the standard of care.
Preclinical Studies: - In vitro studies performed on specific cell lines to have some preliminary results on the activity of a potential product candidate.
- In vivo studies performed on animal models in order to have preliminary results on the dose-dependent toxicity and on the activity of a potential product candidate before further clinical investigation.
IND filing (or foreign equivalent): The Investigational New Drug (IND) filing in the USA consists of submitting the required study documentation package to the health authority (FDA) to obtain the authorization to perform clinical investigation.
Clinical Studies: Testing of the product candidate in humans.

Phases of clinical trials

Phase I: First time an experimental drug or treatment is tested in humans to examine how well the drug is tolerated.
Phase II: Trials designed to examine if the drug or treatment has a clinical activity.
Phase III: Trials designed to assess the treatment effect on a clinically meaningful endpoint.
Phase IV: Post-marketing studies to gain additional information.

Phase I: First time an experimental drug or treatment is tested in humans to examine how well the drug is tolerated.
Phase II: Trials designed to examine if the drug or treatment has a clinical activity.
Phase III: Trials designed to assess the treatment effect on a clinically meaningful endpoint.
Phase IV: Post-marketing studies to gain additional information.

Main Product Candidates

Allogeneic CAR-T Cell Pipeline

Development of a product candidate takes place in several stages

Phases of clinical trials